On June 23, Eli Lilly and Company (NYSE:LLY) declared a quarterly dividend of $1.50 per share, which was in line with its ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

JPMorgan said Eli Lilly is enrolling about 500,000 new obesity drug patients per month, and maintains more than 60% share in ...

Eli Lilly shares weight loss drug market leadership with fellow big pharma player Novo Nordisk. They each commercialize two ...

Eli Lilly (NYSE: LLY) may seem like an expensive stock to invest in right now. It's trading at close to 90 times its trailing earnings. Its $720 billion market capitalization also means it's the ...

There's so much growth on the horizon for Eli Lilly, and with the stock's payout ratio still at a fairly modest 54% of earnings, there is more room for the business to continue making generous ...

Eli Lilly's operating income rose by 75%. For the three-month period ended June 30, Lilly's revenue increased by 36% year over year to $11.3 billion, thanks in large part to the growth in Mounjaro ...

Eli Lilly's shares soar to new highs as it boosts revenue and EPS guidance. ... And to go deeper, sign up for a free trial to Growth Stock Forum. This article was written by. ONeil Trader.

Moreover, Eli Lilly’s stock performance has sparked speculation about a potential split, though its last split occurred in 1997. So, there are plenty of potential catalysts ahead.

Eli Lilly (NYSE: LLY) may seem like an expensive stock to invest in right now. It's trading at close to 90 times its trailing earnings. Its $720 billion market capitalization also means it's the ...